Telix Pharmaceuticals Limited
TLX
$10.67
-$0.07-0.65%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.42M | -2.42M | -1.15M | -1.15M | 7.05M |
| Total Depreciation and Amortization | 5.68M | 5.68M | 4.79M | 4.79M | 1.42M |
| Total Amortization of Deferred Charges | 230.00K | 230.00K | -- | -- | -- |
| Total Other Non-Cash Items | 1.59M | 1.59M | 5.23M | 5.23M | 15.12M |
| Change in Net Operating Assets | -22.61M | -22.61M | -- | -- | -21.51M |
| Cash from Operations | -17.52M | -17.52M | 8.87M | 8.87M | 2.08M |
| Capital Expenditure | -9.51M | -9.51M | -3.33M | -3.33M | -3.03M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 322.50K | 322.50K | -114.84M | -114.84M | -3.81M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -4.34M | -4.34M | -11.26M | -11.26M | -21.29M |
| Cash from Investing | -13.53M | -13.53M | -129.43M | -129.43M | -28.13M |
| Total Debt Issued | 264.50K | 264.50K | -- | -- | 213.06M |
| Total Debt Repaid | -1.23M | -1.23M | -1.80M | -1.80M | -637.50K |
| Issuance of Common Stock | 566.00K | 566.00K | 338.00K | 338.00K | 121.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -4.86M |
| Cash from Financing | -398.00K | -398.00K | -1.46M | -1.46M | 207.68M |
| Foreign Exchange rate Adjustments | -1.19M | -1.19M | 5.59M | 5.59M | -1.14M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -32.65M | -32.65M | -116.42M | -116.42M | 180.49M |